Business Wire

CA-HYPERLOOP-TT

14.7.2020 11:02:12 CEST | Business Wire | Press release

Share
Hyperloop Transportation Technologies and TÜV SÜD Announce Publication of Industry First Complete Safety Guidelines

Hyperloop Transportation Technologies announced today the first ever completed certification guidelines for Hyperloop systems will now be available to the public. The guideline was published in collaboration with HyperloopTT by the internationally recognized TÜV SÜD Group, an industry leading testing, certification, auditing, and advisory services organization. As the European Commission and the United States call for sustainable transportation infrastructure projects, such as Hyperloop, to aid in economic recovery following the pandemic, this guideline paves the way for regulation and adoption. The original guideline was created in 2019 and was shared with governmental transportation and infrastructure organizations in the European Union and United States.

TÜV SÜD reviewed the Hazard Analysis and Risk Assessment (HARA) of the HyperloopTT system and used it as the basis for developing a guideline that defines the key safety requirements for the design, construction, and operation of these systems. The TÜV SÜD guideline took into consideration existing regulations and experience from rail, metro systems, cable cars, amusement rides, aviation, and the process industry, and aligned them to the specific requirements of Hyperloop technology.

Taking a holistic approach, the complete safety guideline defines a host of aspects including the core safety requirements for the transport capsules, the drive system, the environmental control and life support system (ECLSS), the tubes, and the evacuation procedure in case of emergency.

“Our generic guideline is our significant contribution to making an innovative technology like Hyperloop safe and reliable,” says Ferdinand Neuwieser, CEO TÜV SÜD Industrie Service GmbH.

“This is a major milestone for the Hyperloop movement. We are prepared to build the safest form of transportation ever created by humankind,” said Andres De Leon, CEO HyperloopTT. “The work of our teams in collaboration with the experts at TÜV SÜD has created a solid foundation for leading the industry and positioning Hyperloop as an ideal safe and sustainable high speed infrastructure project for the near future.”

Today’s publication represents the full and complete set of safety guidelines. The guideline can be downloaded in PDF format from the TÜV SÜD website for a fee of EUR 1,000: www.tuvsud.com/hyperloop .

About TÜV SÜD

Founded in 1866 as a steam boiler inspection association, the TÜV SÜD Group has evolved into a global enterprise. More than 25,000 employees work at over 1,000 locations in about 50 countries to continually improve technology, systems and expertise. They contribute significantly to making technical innovations such as Industry 4.0, autonomous driving and renewable energy safe and reliable. www.tuvsud.com

About HyperloopTT

Hyperloop Transportation Technologies (HyperloopTT) is an innovative transportation and technology company focused on realizing the Hyperloop, a system that moves people and goods at unprecedented speeds safely, efficiently, and sustainably. Through the use of unique, patented technology and an advanced business model of lean collaboration, open innovation and integrated partnership, HyperloopTT is creating and licensing technologies.

Founded in 2013, HyperloopTT is a global team of more than 800 engineers, creatives and technologists in 52 multidisciplinary teams, with 40 corporate and university partners.

HyperloopTT’s European Research and Development Center is the testing site of the world’s first and only full-scale system and passenger capsule. In 2019, HyperloopTT released the first comprehensive feasibility study analyzing a Hyperloop system, which found that the system is economically and technically feasible and will generate a profit without requiring government subsidies.

Headquartered in Los Angeles, CA and Toulouse, France, HyperloopTT has offices in Abu Dhabi and Dubai, UAE; Bratislava, Slovakia; São Paulo, Brazil; and Barcelona, Spain. HyperloopTT has signed agreements in the United States, UAE, France, Germany, India, China, Korea, Indonesia, Slovakia, Czech Republic, and Ukraine.

For more information or media inquiries, contact press@hyperloop.global or visit http://hyperlooptt.com

Hyperloop Transportation Technologies’ images and assets can be found here

Link:

ClickThru

Social Media:

https://www.facebook.com/hyperlooptt

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye